NervGen Pharma Corp.
NGEN.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 26.00% | -2.63% | -6.89% | -1.34% | 5.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.72% | 39.90% | 38.07% | 15.90% | -10.18% |
| Operating Income | -33.72% | -39.90% | -38.07% | -15.90% | 10.18% |
| Income Before Tax | -13.64% | -24.51% | -5.30% | -20.58% | -20.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.64% | -24.51% | -5.30% | -20.58% | -20.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.64% | -24.51% | -5.30% | -20.58% | -20.68% |
| EBIT | -33.72% | -39.90% | -38.07% | -15.90% | 10.18% |
| EBITDA | -34.17% | -40.56% | -38.56% | -16.31% | 10.08% |
| EPS Basic | -0.74% | -5.74% | 9.24% | -9.78% | -13.11% |
| Normalized Basic EPS | -0.77% | -5.72% | 9.23% | -9.90% | -13.17% |
| EPS Diluted | -0.74% | -5.74% | 9.24% | -9.78% | -13.11% |
| Normalized Diluted EPS | -0.77% | -5.72% | 9.23% | -9.90% | -13.17% |
| Average Basic Shares Outstanding | 13.47% | 17.73% | 13.94% | 9.91% | 5.97% |
| Average Diluted Shares Outstanding | 13.47% | 17.73% | 13.94% | 9.91% | 5.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |